Introduction
The stakeholders involved in the American therapeutic Inc case; include the company American Therapeutics Inc, which is a firm that specializes in the manufacture of so-called Generic drugs. This company is one of the stakeholders is based in the Bohemia region in New York. The other stakeholder, in this case, is Raju V. Vegesna, who is the president of the American Therapeutic Inc institution. The other stakeholder involved in this case is the Food and Drug Administration agency; which is the firm responsible for the approval of the Generic brands manufactured by the Generic drug manufacturing companies; before they’re allowed to enter the market.
The case
Another minor stakeholder in this case who is not directly involved in this case but the long-term functioning of the chain; are the customers as they constitute the clientele for the Generic products. Another minor stakeholder mentioned in the case is the Mead Johnson Company; whose patent for Desyrel was expiring paving the way for the marketing of Trazodone Hydrochloride by the American Therapeutic firm. Another stakeholder, in this case, is Charles Y. Chang; who is a top FDA generic drug review chemist. The other stakeholder mentioned in the case is Jan T. Sturm; who was an FDA consumer safety officer.
On the part of Vegesna; he violated the ethical principle of the common good, as he arranged for the bribing of Chang and Sturm so that they could work to ensure that Trazodone was approved without going through the due process. Chang violated the ethical principle of beneficence which seeks that one should avoid evil by doing well; which is not the case as he aided in the approval of the drug as opposed to the due process. Sturm violated the ethical principle of the common good; as he acted in favor of the approval of the drug for his selfish interests and gain.
The liabilities associated with Vegesna’s actions are that; approval of the drug without going through the due process can mean a far-reaching disadvantage to the consumers of the product. This is evident from the fact that he did not want the product to go through laboratory analysis; as he possibly knew that it would not receive approval. The other liability associated with the actions of Vegesna is that he may have to make more fake realities and lies like the one of declaring that the laboratory had been eliminated; which will need further ills to help cover up the problem he has created, to the parties involved including the customer population.
Vegesna did not have any other means or way to get quick FDA approval; as it is evident that he decided to take this shortcut on finding out that the agency had decided to Laboratory test the drug. From the monitoring of the process of approval from the inside source of Sturm; it is also indicative that he was convinced that if he was to face the challenges involved in the formal approval or competition in the process, his drug would not have received the approval.
Conclusion
The fact that the two corrupt officials received bribes from Vegesna implies that the same individuals are capable of blackmailing him to make more payments to them, or they unveil the lies underlying the approval. As a move to ensure that no more payments are made in the future; Vegesna should do all he can to have his brand approved lawfully. This will help in that the greedy officials will not turn against him in the future to demand more payments. However, there is a risk involved that; attempting to seek lawful approval may reveal the reality behind the previous approval risking his brand’s cancellation.